18. Spinocerebellar degeneration Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 76 / Drugs : 98 - (DrugBank : 31) / Drug target genes : 44 - Drug target pathways : 65
Drugs and their primary sponsors and trial info
Alpha-tocotrienolquinone
PTC Therapeutics, Inc.
2021 Phase 2;Phase 3 EUCTR2020-002812-36-FR Australia;Brazil;Canada;France;Germany;Italy;New Zealand;Spain;United States;
2021 Phase 2;Phase 3 EUCTR2020-002812-36-ES Australia;Brazil;Canada;France;Germany;Italy;Spain;United States;
2021 Phase 2;Phase 3 EUCTR2020-002812-36-DE Australia;Brazil;Canada;France;Germany;Italy;New Zealand;Spain;United States;
Artesunate
INSERM
2021 Phase 1;Phase 2 EUCTR2021-000171-36-FR France;
Artesunate Oral Product
Institut National de la Santé Et de la Recherche Médicale, France
2021 Phase 1/Phase 2 NCT04921930 -
BINOCRIT*1SIR 40000UI/1ML
UNIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II
2012 Phase 2 EUCTR2011-006156-37-IT Italy;
Baclofen
DAIICHI SANKYO COMPANY, LIMITED
- Phase 4 JPRN-JapicCTI-050031 -
Bupropion & Citalopram
University of Colorado, Denver
2012 Phase 4 NCT01716221 -
Butylphthalide
Xiangya Hospital of Central South University
2017 Phase 2 study ChiCTR-IIR-17012717 China;
C-Trelin OD Tab(5mg Taltirelin Hydrate)
MediForum Pharm
2019 Phase 4 NCT04107740 Korea, Republic of;
CTI-1601
Larimar Therapeutics, Inc.
2020 Phase 1 NCT04519567 United States;
2019 Phase 1 NCT04176991 United States;
Cabaletta for IV infusion once weekly during 24 weeks
Bioblast Pharma Ltd.
2014 Phase 2 NCT02147886 Israel;
Calcitriol
Berta Alemany
2021 Phase 4 NCT04801303 Spain;
Coenzyme Q10
Department of Neurology, Tokushima University, Japan
2018 - JPRN-UMIN000031788 Japan;
DT-216
Design Therapeutics
2022 Phase 1 NCT05285540 United States;
Deferiprone
APOPHARMA INC., TORONTO, ONTARIO
2009 - EUCTR2009-010865-22-IT Belgium;France;Italy;Spain;
2008 - EUCTR2007-003331-23-IT Belgium;France;Italy;Spain;United Kingdom;
EGB 761 (r)
BEAUFOUR IPSEN PHARMA
2008 - EUCTR2007-005371-34-FR France;
EGb 761
Ipsen
2008 Phase 2 NCT00824512 France;
EPREX*1FL 40000UI/ML 1ML
ISTITUTO NEUROLOGICO CARLO BESTA
2007 - EUCTR2007-003357-85-IT Italy;
EPREX*1SIR 10000UI 1ML
UNIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II
2012 Phase 2 EUCTR2011-006156-37-IT Italy;
EPREX*1SIR 40000UI/ML 1ML
UNIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II
2012 Phase 2 EUCTR2011-006156-37-IT Italy;
EU1/97/031-032
Medizinische Universität Innsbruck, Univ.-Klinik für Neurologie
2009 Phase 2 EUCTR2008-000040-13-AT Austria;
EU1/97/031/031-032
Dr. Sylvia Boesch
2006 Phase 2 EUCTR2005-005938-12-AT Austria;
Epoeitin beta
Medizinische Universität Innsbruck, Univ.-Klinik für Neurologie
2009 Phase 2 EUCTR2008-000040-13-AT Austria;
Epoetin alfa
Federico II University
2013 Phase 2 NCT01493973 Italy;
Erythropoietin
ISTITUTO NEUROLOGICO CARLO BESTA
2007 - EUCTR2007-003357-85-IT Italy;
Etravirine Tablets
IRCCS Eugenio Medea
2020 Phase 2 NCT04273165 Italy;
Flumazenil
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
2013 - JPRN-UMIN000011111 Japan;
Gamma interferon
Azienda Policlinico Umberto I
2013 Phase 2 NCT02035020 Italy;
IRCCS Eugenio Medea
2016 Phase 2 NCT03888664 -
Glentek 50 mg compresse rivestite con film
DIPARTIMENTO DI NEUROSCIENZE SALUTE MENTALE E ORGANI DI SENSO - NESMOS - SAPIENZA UNIVERSITÀ DI ROMA
2020 Phase 2 EUCTR2018-000282-37-IT Italy;United States;
Glentek 50 mg film-coated tablets
DIPARTIMENTO DI NEUROSCIENZE SALUTE MENTALE E ORGANI DI SENSO - NESMOS - SAPIENZA UNIVERSITÀ DI ROMA
2020 Phase 2 EUCTR2018-000282-37-IT Italy;United States;
Granocyte
University of Bristol
2018 Phase 2 EUCTR2017-003084-34-GB United Kingdom;
H-116PI-DE.pdf
Medizinische Universität Innsbruck, Univ.-Klinik für Neurologie
2009 Phase 2 EUCTR2008-000040-13-AT Austria;
High-dose intravenous immunoglobulin (IVIG)
National Institute of Neurological Disorders and Stroke (NINDS)
2002 Phase 2 NCT00034242 United States;
IMUKIN - 6 FLACONI 0.5 ML 100 MCG
ASSOCIAZIONE LA NOSTRA FAMIGLIA - SEZIONE SCIENTIFICA I.R.C.C.S. E.MEDEA
2016 Phase 2 EUCTR2015-002432-40-IT Italy;
IMUKIN*SC 6F 0,5ML 100MCG
AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
2013 - EUCTR2012-001881-14-IT Italy;
INTELENCE - 200 MG - COMPRESSA -USO ORALE - FLACONE (HDPE) 60 COMPRESSE
ASSOCIAZIONE LA NOSTRA FAMIGLIA - SEZIONE SCIENTIFICA I.R.C.C.S. E.MEDEA
2020 Phase 2 EUCTR2019-002618-38-IT Italy;
Idebenone
National Institute of Neurological Disorders and Stroke (NINDS)
2005 Phase 2 NCT00229632 United States;
2004 Phase 1 NCT00078481 United States;
2001 Phase 1 NCT00015808 United States;
Iron chelating intervention
Assistance Publique - Hôpitaux de Paris
2005 Phase 1/Phase 2 NCT00224640 France;
J05AG04
ASSOCIAZIONE LA NOSTRA FAMIGLIA - SEZIONE SCIENTIFICA I.R.C.C.S. E.MEDEA
2020 Phase 2 EUCTR2019-002618-38-IT Italy;
KPS-0373
Kissei Pharmaceutical Co., Ltd.
2016 Phase 3 NCT02889302 Japan;
2011 Phase 2 NCT01384435 Japan;
2009 Phase 2 NCT01004016 Japan;
2004 Phase 2 NCT00863538 Japan;
KPS-0373, High dose
Kissei Pharmaceutical Co., Ltd.
2013 Phase 3 NCT01970137 Japan;
2013 Phase 3 NCT01970124 Japan;
2013 Phase 3 NCT01970111 Japan;
2013 Phase 3 NCT01970098 Japan;
KPS-0373, Low dose
Kissei Pharmaceutical Co., Ltd.
2013 Phase 3 NCT01970137 Japan;
2013 Phase 3 NCT01970124 Japan;
2013 Phase 3 NCT01970111 Japan;
2013 Phase 3 NCT01970098 Japan;
Lenograstim
University of Bristol
2018 Phase 2 EUCTR2017-003084-34-GB United Kingdom;
Lu AA24493
H. Lundbeck A/S
2009 - EUCTR2008-003662-25-AT Austria;Germany;Italy;
- - EUCTR2008-003662-25-DE Austria;Germany;Italy;
H.Lundbeck A/S
2009 - EUCTR2008-003662-25-IT Austria;Germany;Italy;
MIB-626
Metro International Biotech, LLC
2021 Phase 2 NCT04817111 United States;
MIN-102
Minoryx Therapeutics, S.L.
2019 Phase 2 NCT03917225 Belgium;France;Germany;Spain;
Methylprednisolone
Children's Hospital of Philadelphia
2015 Early Phase 1 NCT02424435 United States;
Neo-Recormon
Dr. Sylvia Boesch
2006 Phase 2 EUCTR2005-005938-12-AT Austria;
Neorecormon
Medizinische Universität Innsbruck, Univ.-Klinik für Neurologie
2009 Phase 2 EUCTR2008-000040-13-AT Austria;
Nicotinamide
RWTH Aachen University
2022 Phase 2 NCT03761511 Austria;France;Germany;Italy;Spain;United Kingdom;
RWTH Aachen University, Center for Translational & Clinical Research Aachen (CTC-A)
2020 Phase 2;Phase 3 EUCTR2017-002163-17-GB Austria;Germany;Spain;United Kingdom;
Omaveloxolone Capsules,
Reata Pharmaceuticals, Inc.
2015 Phase 2 NCT02255435 Australia;Austria;Brazil;Italy;United Kingdom;United States;
PTC743
PTC THERAPEUTICS INC.
2021 Phase 2;Phase 3 EUCTR2020-002812-36-IT Australia;Brazil;Canada;France;Germany;Italy;Spain;United States;
PTC Therapeutics, Inc.
2021 Phase 2;Phase 3 EUCTR2020-002812-36-FR Australia;Brazil;Canada;France;Germany;Italy;New Zealand;Spain;United States;
2021 Phase 2;Phase 3 EUCTR2020-002812-36-ES Australia;Brazil;Canada;France;Germany;Italy;Spain;United States;
2021 Phase 2;Phase 3 EUCTR2020-002812-36-DE Australia;Brazil;Canada;France;Germany;Italy;New Zealand;Spain;United States;
RHuG-CSF
University of Bristol
2018 Phase 2 EUCTR2017-003084-34-GB United Kingdom;
Resveratrol
Murdoch Childrens Research Institute
2019 Phase 2 NCT03933163 Australia;
2011 Phase 1/Phase 2 NCT01339884 Australia;
Riluzole
S. Andrea Hospital
2019 Phase 2/Phase 3 NCT03660917 Italy;
Riluzole PMCS
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2017 Phase 3 EUCTR2017-001481-23-FR France;
Riluzolo
DIPARTIMENTO DI NEUROSCIENZE SALUTE MENTALE E ORGANI DI SENSO - NESMOS - SAPIENZA UNIVERSITÀ DI ROMA
2020 Phase 2 EUCTR2018-000282-37-IT Italy;United States;
Rokan (r) Novo
BEAUFOUR IPSEN PHARMA
2008 - EUCTR2007-005371-34-FR France;
Rosuvastatin
Children's Hospital of Philadelphia
2016 Early Phase 1 NCT02705547 United States;
SUB09246MIG
RWTH Aachen University, Center for Translational & Clinical Research Aachen (CTC-A)
2020 Phase 2;Phase 3 EUCTR2017-002163-17-GB Austria;Germany;Spain;United Kingdom;
Standardized Ginkgo Biloba Extract (EGb 761 (r)
BEAUFOUR IPSEN PHARMA
2008 - EUCTR2007-005371-34-FR France;
TAK-831
Neurocrine Biosciences
2017 Phase 2 NCT03214588 United States;
Varenicline
Niigata University
2013 Phase 1,2 JPRN-UMIN000011560 Japan;
Vatiquinone
PTC THERAPEUTICS INC.
2021 Phase 2;Phase 3 EUCTR2020-002812-36-IT Australia;Brazil;Canada;France;Germany;Italy;Spain;United States;
PTC Therapeutics
2020 Phase 2/Phase 3 NCT04577352 Australia;Brazil;Canada;France;Germany;Italy;New Zealand;Spain;United States;
PTC Therapeutics, Inc.
2021 Phase 2;Phase 3 EUCTR2020-002812-36-FR Australia;Brazil;Canada;France;Germany;Italy;New Zealand;Spain;United States;
2021 Phase 2;Phase 3 EUCTR2020-002812-36-ES Australia;Brazil;Canada;France;Germany;Italy;Spain;United States;
2021 Phase 2;Phase 3 EUCTR2020-002812-36-DE Australia;Brazil;Canada;France;Germany;Italy;New Zealand;Spain;United States;
Artesunate
INSERM
2021 Phase 1;Phase 2 EUCTR2021-000171-36-FR France;
Artesunate Oral Product
Institut National de la Santé Et de la Recherche Médicale, France
2021 Phase 1/Phase 2 NCT04921930 -
BINOCRIT*1SIR 40000UI/1ML
UNIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II
2012 Phase 2 EUCTR2011-006156-37-IT Italy;
Baclofen
DAIICHI SANKYO COMPANY, LIMITED
- Phase 4 JPRN-JapicCTI-050031 -
Bupropion & Citalopram
University of Colorado, Denver
2012 Phase 4 NCT01716221 -
Butylphthalide
Xiangya Hospital of Central South University
2017 Phase 2 study ChiCTR-IIR-17012717 China;
C-Trelin OD Tab(5mg Taltirelin Hydrate)
MediForum Pharm
2019 Phase 4 NCT04107740 Korea, Republic of;
CTI-1601
Larimar Therapeutics, Inc.
2020 Phase 1 NCT04519567 United States;
2019 Phase 1 NCT04176991 United States;
Cabaletta for IV infusion once weekly during 24 weeks
Bioblast Pharma Ltd.
2014 Phase 2 NCT02147886 Israel;
Calcitriol
Berta Alemany
2021 Phase 4 NCT04801303 Spain;
Coenzyme Q10
Department of Neurology, Tokushima University, Japan
2018 - JPRN-UMIN000031788 Japan;
DT-216
Design Therapeutics
2022 Phase 1 NCT05285540 United States;
Deferiprone
APOPHARMA INC., TORONTO, ONTARIO
2009 - EUCTR2009-010865-22-IT Belgium;France;Italy;Spain;
2008 - EUCTR2007-003331-23-IT Belgium;France;Italy;Spain;United Kingdom;
EGB 761 (r)
BEAUFOUR IPSEN PHARMA
2008 - EUCTR2007-005371-34-FR France;
EGb 761
Ipsen
2008 Phase 2 NCT00824512 France;
EPREX*1FL 40000UI/ML 1ML
ISTITUTO NEUROLOGICO CARLO BESTA
2007 - EUCTR2007-003357-85-IT Italy;
EPREX*1SIR 10000UI 1ML
UNIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II
2012 Phase 2 EUCTR2011-006156-37-IT Italy;
EPREX*1SIR 40000UI/ML 1ML
UNIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II
2012 Phase 2 EUCTR2011-006156-37-IT Italy;
EU1/97/031-032
Medizinische Universität Innsbruck, Univ.-Klinik für Neurologie
2009 Phase 2 EUCTR2008-000040-13-AT Austria;
EU1/97/031/031-032
Dr. Sylvia Boesch
2006 Phase 2 EUCTR2005-005938-12-AT Austria;
Epoeitin beta
Medizinische Universität Innsbruck, Univ.-Klinik für Neurologie
2009 Phase 2 EUCTR2008-000040-13-AT Austria;
Epoetin alfa
Federico II University
2013 Phase 2 NCT01493973 Italy;
Erythropoietin
ISTITUTO NEUROLOGICO CARLO BESTA
2007 - EUCTR2007-003357-85-IT Italy;
Etravirine Tablets
IRCCS Eugenio Medea
2020 Phase 2 NCT04273165 Italy;
Flumazenil
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
2013 - JPRN-UMIN000011111 Japan;
Gamma interferon
Azienda Policlinico Umberto I
2013 Phase 2 NCT02035020 Italy;
IRCCS Eugenio Medea
2016 Phase 2 NCT03888664 -
Glentek 50 mg compresse rivestite con film
DIPARTIMENTO DI NEUROSCIENZE SALUTE MENTALE E ORGANI DI SENSO - NESMOS - SAPIENZA UNIVERSITÀ DI ROMA
2020 Phase 2 EUCTR2018-000282-37-IT Italy;United States;
Glentek 50 mg film-coated tablets
DIPARTIMENTO DI NEUROSCIENZE SALUTE MENTALE E ORGANI DI SENSO - NESMOS - SAPIENZA UNIVERSITÀ DI ROMA
2020 Phase 2 EUCTR2018-000282-37-IT Italy;United States;
Granocyte
University of Bristol
2018 Phase 2 EUCTR2017-003084-34-GB United Kingdom;
H-116PI-DE.pdf
Medizinische Universität Innsbruck, Univ.-Klinik für Neurologie
2009 Phase 2 EUCTR2008-000040-13-AT Austria;
High-dose intravenous immunoglobulin (IVIG)
National Institute of Neurological Disorders and Stroke (NINDS)
2002 Phase 2 NCT00034242 United States;
IMUKIN - 6 FLACONI 0.5 ML 100 MCG
ASSOCIAZIONE LA NOSTRA FAMIGLIA - SEZIONE SCIENTIFICA I.R.C.C.S. E.MEDEA
2016 Phase 2 EUCTR2015-002432-40-IT Italy;
IMUKIN*SC 6F 0,5ML 100MCG
AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
2013 - EUCTR2012-001881-14-IT Italy;
INTELENCE - 200 MG - COMPRESSA -USO ORALE - FLACONE (HDPE) 60 COMPRESSE
ASSOCIAZIONE LA NOSTRA FAMIGLIA - SEZIONE SCIENTIFICA I.R.C.C.S. E.MEDEA
2020 Phase 2 EUCTR2019-002618-38-IT Italy;
Idebenone
National Institute of Neurological Disorders and Stroke (NINDS)
2005 Phase 2 NCT00229632 United States;
2004 Phase 1 NCT00078481 United States;
2001 Phase 1 NCT00015808 United States;
Iron chelating intervention
Assistance Publique - Hôpitaux de Paris
2005 Phase 1/Phase 2 NCT00224640 France;
J05AG04
ASSOCIAZIONE LA NOSTRA FAMIGLIA - SEZIONE SCIENTIFICA I.R.C.C.S. E.MEDEA
2020 Phase 2 EUCTR2019-002618-38-IT Italy;
KPS-0373
Kissei Pharmaceutical Co., Ltd.
2016 Phase 3 NCT02889302 Japan;
2011 Phase 2 NCT01384435 Japan;
2009 Phase 2 NCT01004016 Japan;
2004 Phase 2 NCT00863538 Japan;
KPS-0373, High dose
Kissei Pharmaceutical Co., Ltd.
2013 Phase 3 NCT01970137 Japan;
2013 Phase 3 NCT01970124 Japan;
2013 Phase 3 NCT01970111 Japan;
2013 Phase 3 NCT01970098 Japan;
KPS-0373, Low dose
Kissei Pharmaceutical Co., Ltd.
2013 Phase 3 NCT01970137 Japan;
2013 Phase 3 NCT01970124 Japan;
2013 Phase 3 NCT01970111 Japan;
2013 Phase 3 NCT01970098 Japan;
Lenograstim
University of Bristol
2018 Phase 2 EUCTR2017-003084-34-GB United Kingdom;
Lu AA24493
H. Lundbeck A/S
2009 - EUCTR2008-003662-25-AT Austria;Germany;Italy;
- - EUCTR2008-003662-25-DE Austria;Germany;Italy;
H.Lundbeck A/S
2009 - EUCTR2008-003662-25-IT Austria;Germany;Italy;
MIB-626
Metro International Biotech, LLC
2021 Phase 2 NCT04817111 United States;
MIN-102
Minoryx Therapeutics, S.L.
2019 Phase 2 NCT03917225 Belgium;France;Germany;Spain;
Methylprednisolone
Children's Hospital of Philadelphia
2015 Early Phase 1 NCT02424435 United States;
Neo-Recormon
Dr. Sylvia Boesch
2006 Phase 2 EUCTR2005-005938-12-AT Austria;
Neorecormon
Medizinische Universität Innsbruck, Univ.-Klinik für Neurologie
2009 Phase 2 EUCTR2008-000040-13-AT Austria;
Nicotinamide
RWTH Aachen University
2022 Phase 2 NCT03761511 Austria;France;Germany;Italy;Spain;United Kingdom;
RWTH Aachen University, Center for Translational & Clinical Research Aachen (CTC-A)
2020 Phase 2;Phase 3 EUCTR2017-002163-17-GB Austria;Germany;Spain;United Kingdom;
Omaveloxolone Capsules,
Reata Pharmaceuticals, Inc.
2015 Phase 2 NCT02255435 Australia;Austria;Brazil;Italy;United Kingdom;United States;
PTC743
PTC THERAPEUTICS INC.
2021 Phase 2;Phase 3 EUCTR2020-002812-36-IT Australia;Brazil;Canada;France;Germany;Italy;Spain;United States;
PTC Therapeutics, Inc.
2021 Phase 2;Phase 3 EUCTR2020-002812-36-FR Australia;Brazil;Canada;France;Germany;Italy;New Zealand;Spain;United States;
2021 Phase 2;Phase 3 EUCTR2020-002812-36-ES Australia;Brazil;Canada;France;Germany;Italy;Spain;United States;
2021 Phase 2;Phase 3 EUCTR2020-002812-36-DE Australia;Brazil;Canada;France;Germany;Italy;New Zealand;Spain;United States;
RHuG-CSF
University of Bristol
2018 Phase 2 EUCTR2017-003084-34-GB United Kingdom;
Resveratrol
Murdoch Childrens Research Institute
2019 Phase 2 NCT03933163 Australia;
2011 Phase 1/Phase 2 NCT01339884 Australia;
Riluzole
S. Andrea Hospital
2019 Phase 2/Phase 3 NCT03660917 Italy;
Riluzole PMCS
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2017 Phase 3 EUCTR2017-001481-23-FR France;
Riluzolo
DIPARTIMENTO DI NEUROSCIENZE SALUTE MENTALE E ORGANI DI SENSO - NESMOS - SAPIENZA UNIVERSITÀ DI ROMA
2020 Phase 2 EUCTR2018-000282-37-IT Italy;United States;
Rokan (r) Novo
BEAUFOUR IPSEN PHARMA
2008 - EUCTR2007-005371-34-FR France;
Rosuvastatin
Children's Hospital of Philadelphia
2016 Early Phase 1 NCT02705547 United States;
SUB09246MIG
RWTH Aachen University, Center for Translational & Clinical Research Aachen (CTC-A)
2020 Phase 2;Phase 3 EUCTR2017-002163-17-GB Austria;Germany;Spain;United Kingdom;
Standardized Ginkgo Biloba Extract (EGb 761 (r)
BEAUFOUR IPSEN PHARMA
2008 - EUCTR2007-005371-34-FR France;
TAK-831
Neurocrine Biosciences
2017 Phase 2 NCT03214588 United States;
Varenicline
Niigata University
2013 Phase 1,2 JPRN-UMIN000011560 Japan;
Vatiquinone
PTC THERAPEUTICS INC.
2021 Phase 2;Phase 3 EUCTR2020-002812-36-IT Australia;Brazil;Canada;France;Germany;Italy;Spain;United States;
PTC Therapeutics
2020 Phase 2/Phase 3 NCT04577352 Australia;Brazil;Canada;France;Germany;Italy;New Zealand;Spain;United States;